China VC Fund Formed to Invest in Israeli Life Science Startups

The $100 million Guangzhou-Israel Bio Fund will focus on forming joint ventures with Israelis in China.

Ora Coren
Ora Coren
Send in e-mailSend in e-mail
Biotech research.
Biotech research.Credit: Haaretz
Ora Coren
Ora Coren

Yehoshua Gleitman, a former chief scientist at the Economy Ministry, has formed a $100 million Chinese venture capital fund to invest in Israeli life science companies, in a move marking a major new step in the two countries’ high-tech partnership.

The Guangzhou-Israel Bio Fund will be managed by a joint Israeli-Chinese team headed by Gleitman. Its backers include the Guangzhou municipal government and three Chinese companies, among them one of the country’s biggest pharmaceutical firms.

“Life sciences is one of the most developing fields in China, which has set itself an ambitious target, namely that 3% of gross domestic product will come in another 15 years from activities in this area,” Gleitman said.

“Living standards are growing quickly and a growing middle class has created huge demand for advanced medicine. As a result, the pace of change and the transitions from traditional medicine to Western medicine have been great,” he said, predicting that China would become in less than a decade the world’s largest market for drugs and medical devices.

The fund will invest in Israeli biotech and medical device startups that are at a relatively advanced stage in developing new technology and are relatively low-risk investments. They will be offered to set up Chinese subsidiaries in Guangzhou that will be responsible for completing development and enjoy exclusive rights in the Chinese market.

The fund said it was already investigating collaboration with five Israeli startups in pharma and medical devices.

Gleitman said the Guangzhou subsidiaries would be operated as equally owned joint ventures between the Israeli startups and the fund. A startup would transfer all knowledge right rights for the Chinese market to a joint venture but retain them for other world markets.

In return, the Guangzhou-Israel Bio Fund would fund the joint venture and help ensure it an attractive exit; for example, through an initial public offering on the Chinese stock market.

The fund was set up to run for seven years, with investments being made over the first five. The fund managers will take a 2% management fee.

“We believe that this is an innovative model with many advantages for Israeli companies,” Gleutman said. “Penetrating the Chinese market is very difficult if not impossible for Israeli companies. Beyond the ordinary problems of language and culture, in life sciences you have to cope with local regulations that are very complicated.”

He cited a tendency for Chinese regulators to favor local players and in many cases bar imports altogether. “So for foreign companies with limited resources we’re talking about a long process with low chances of success,” he said.

Gleitman added that the fund’s Chinese investors had asked the Israeli members of the management team to build a platform that would enable the companies to invest directly in the Israeli startups forming joint ventures with the fund.

Click the alert icon to follow topics:



Automatic approval of subscriber comments.

Already signed up? LOG IN


הקלטות מעוז

Jewish Law Above All: Recordings Reveal Far-right MK's Plan to Turn Israel Into Theocracy

איתמר בן גביר

Why I’m Turning My Back on My Jewish Identity

Travelers looking at the Departures board at Ben Gurion Airport. The number of olim who later become yordim is unknown.

Down and Out: Why These New Immigrants Ended Up Leaving Israel

Beatrice Grannò and Simona Tabasco as Mia and Lucia in "The White Lotus."

The Reality Behind ‘The White Lotus’ Sex Work Fantasy

The Mossad hit team in Dubai. Exposed by dozens of security cameras

This ‘Dystopian’ Cyber Firm Could Have Saved Mossad Assassins From Exposure

מליאת הכנסת 28.12.22

Comeback Kid: How Netanyahu Took Back Power After 18 Months in Exile